• Filing Date: 2021-04-16
  • Form Type: 10-K/A
  • Description: Annual report (Amendment)
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2020
Mar. 25, 2021
Jun. 30, 2020
Cover [Abstract]      
Entity Registrant Name TENAX THERAPEUTICS, INC.    
Entity Central Index Key 0000034956    
Document Type 10-K/A    
Document Period End Date Dec. 31, 2020    
Amendment Flag true    
Amendment Description This Amendment No. 1 (this “Amendment”) to the Annual Report on Form 10-K filed on March 31, 2021 (the “Original Annual Report”) of Tenax Therapeutics, Inc. (the “Company”) is being filed solely for the purpose of correcting certain inadvertent errors in the net loss per share and weighted average number of shares items of the Consolidated Statements of Operations and Comprehensive Loss presented under the Caption “Financial Statements and Supplementary Data” on page 37 of the Original Annual Report by amending and restating only the Consolidated Statements of Operations and Comprehensive Loss appearing in Part II, Item 8. “Financial Statements Supplementary Data” in the Original Annual Report. Except as described above, no other changes have been made to the Original Annual Report. We have not updated the disclosures contained therein to reflect any events which occurred at a date subsequent to the filing of the Original Annual Report. The Company has included as exhibits to this Amendment updated certifications from the Company’s Principal Executive Officer and Principal Financial Officer pursuant to Sections 302 and 906 of the Sarbanes Oxley Act.    
Current Fiscal Year End Date --12-31    
Is Entity a Well-known Seasoned Issuer? No    
Is Entity a Voluntary Filer? No    
Is Entity's Reporting Status Current? Yes    
Entity Filer Category Non-accelerated Filer    
Entity Emerging Growth Company false    
Entity Small Business true    
Entity Shell Company false    
Entity Interactive Data Current Yes    
Entity Incorporation, State or Country Code DE    
Entity File Number 001-34600    
Entity Public Float     $ 9,099,973
Entity Common Stock, Shares Outstanding   14,969,312  
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2020